ES2158425T3 - Procedimiento para la preparacion de derivados de pirimidina. - Google Patents

Procedimiento para la preparacion de derivados de pirimidina.

Info

Publication number
ES2158425T3
ES2158425T3 ES97119003T ES97119003T ES2158425T3 ES 2158425 T3 ES2158425 T3 ES 2158425T3 ES 97119003 T ES97119003 T ES 97119003T ES 97119003 T ES97119003 T ES 97119003T ES 2158425 T3 ES2158425 T3 ES 2158425T3
Authority
ES
Spain
Prior art keywords
alkyl
procedure
preparation
carbanionic
chem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97119003T
Other languages
English (en)
Spanish (es)
Inventor
Wolfgang Gohring
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2158425T3 publication Critical patent/ES2158425T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ES97119003T 1996-11-08 1997-10-31 Procedimiento para la preparacion de derivados de pirimidina. Expired - Lifetime ES2158425T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH275796 1996-11-08

Publications (1)

Publication Number Publication Date
ES2158425T3 true ES2158425T3 (es) 2001-09-01

Family

ID=4240937

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97119003T Expired - Lifetime ES2158425T3 (es) 1996-11-08 1997-10-31 Procedimiento para la preparacion de derivados de pirimidina.

Country Status (9)

Country Link
US (3) US5883254A (da)
EP (1) EP0841326B1 (da)
JP (1) JP3805502B2 (da)
KR (1) KR100535450B1 (da)
CN (1) CN1109023C (da)
AT (1) ATE201201T1 (da)
DE (1) DE69704832T2 (da)
DK (1) DK0841326T3 (da)
ES (1) ES2158425T3 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1454908B1 (en) * 2003-03-07 2008-02-27 Sanofi-Aventis Substituted pyridinyl-2-(diaza-bicyclo-alkyl)-pyrimidinone derivatives
EP1454910A1 (en) 2003-03-07 2004-09-08 Sanofi-Synthelabo Substituted pyrimidinyl-2-(diaza-bicyclo-alkyl)-pyrimidone derivatives
DK1603910T3 (da) * 2003-03-07 2009-11-23 Sanofi Aventis Substituerede 2-(diazabicykloalkyl)-pyrimidon-derivater
CL2004000545A1 (es) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul
DE102004022897A1 (de) * 2004-05-10 2005-12-08 Bayer Cropscience Ag Azinyl-imidazoazine
WO2007119214A2 (en) * 2006-04-13 2007-10-25 Actelion Pharmaceuticals Ltd Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
ATE530531T1 (de) * 2007-12-18 2011-11-15 Dipharma Francis Srl Verfahren zur herstellung von bosentan
EP2250999B1 (en) * 2008-02-08 2016-04-13 Shiseido Company, Ltd. Skin whitening agent and external preparation for the skin
CA2758108A1 (en) 2009-04-13 2010-10-21 Sandoz Ag Process for preparation of endothelial receptor antagonist (bosentan)
WO2011070049A1 (en) 2009-12-09 2011-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Endothelin inhibitors for the treatment of rapidly progressive glomerulonephritis
KR102004422B1 (ko) * 2012-12-20 2019-07-26 제일약품주식회사 보센탄 일수화물의 제조방법, 이에 사용되는 신규 중간체 및 이의 제조방법
WO2018185516A1 (en) 2017-04-05 2018-10-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
CN116410141A (zh) * 2021-12-31 2023-07-11 南京艾德凯腾生物医药有限责任公司 一种阿伐那非中间体的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH423708A (de) * 1961-12-08 1966-06-30 Ciba Geigy Verfahren zum Färben und Bedrucken von Textilmaterialien
BE625803A (da) * 1961-12-08
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
WO1995012313A1 (en) * 1993-11-05 1995-05-11 Pathogenesis Corporation Virus associated multiple sclerosis: treatments, prevention and diagnosis thereof

Also Published As

Publication number Publication date
US5883254A (en) 1999-03-16
JP3805502B2 (ja) 2006-08-02
EP0841326A1 (en) 1998-05-13
DK0841326T3 (da) 2001-07-23
EP0841326B1 (en) 2001-05-16
US6121447A (en) 2000-09-19
KR100535450B1 (ko) 2006-03-30
DE69704832T2 (de) 2001-11-29
US6274734B1 (en) 2001-08-14
CN1182082A (zh) 1998-05-20
CN1109023C (zh) 2003-05-21
KR19980041968A (ko) 1998-08-17
ATE201201T1 (de) 2001-06-15
DE69704832D1 (de) 2001-06-21
JPH10139765A (ja) 1998-05-26

Similar Documents

Publication Publication Date Title
FI935529A0 (fi) Aminometylensubstituerade icke-aromatiska heterocykliska foereningar
PT1369409E (pt) Sais do acido boronico e sua utilizacao na preparacao de medicamentos para o tratamento da trombose
DK0758335T3 (da) Fremstilling af et camptothecinderivat ved intramolekylær ringslutning
ES2175624T3 (es) Derivados de pirazolo(4,3-d)pirimidina y composiciones farmaceuticas que los contienen.
ES2195510T3 (es) Derivados de imidazopiridina y procedimiento para prepararlos.
EP0896533A4 (en) PENTAFLUOROBENZEN SULPHONAMIDES AND ANALOGS
DE60012751D1 (de) Verwendung von ep4 rezeptorliganden zur behandlung von neuropathischen schmerz
DE69418243D1 (de) N-Heteroaryl-N'-Phenylharnstoffderivate, ihre Herstellung und Verwendung
PT918776E (pt) Sintese total de acilfulvenos antitumorais
DK0841326T3 (da) Fremgangsmåde til fremstilling af pyrimidinderivater
ES2150808T3 (es) Forma cristalina de (4-trifluorometil)-anilida de acido 5-metilisoxazol-4-carboxilico.
NZ228065A (en) 1,2,4-triazinediones and parasiticidal compositions; processes for preparation
BR9807988A (pt) Processo para a preparação de um composto, e, composto.
ATE90348T1 (de) Pyrido(2,3-d>pyrimidin-derivate.
BR0013751A (pt) Processo para produção de derivados de ácido naftiridina-3-carboxìlico
BR9503845A (pt) Processo para a preparação de um composto e composto obtido
BR9810481A (pt) Processo para preparação de 1h-indol-3-glioxamidas 4-substituìdas.
DE3671628D1 (de) Norfloxacin-zwischenverbindung.
ES2053707T3 (es) Procedimiento para la preparacion de amidas de acidos 3,3-diaril-acrilicos.
MX9100345A (es) Procedimiento para la preparacion de derivados 6-(aminopropionil sustituidos)de forscolina
DE69724216D1 (de) Pyridin-Zwischenprodukte, verwendbar zur Herstellung von Beta-adrenergischen Rezeptor-Agonisten
BR9909697A (pt) Processo para preparação de 1h-indol-3-glioxamidas 4-substituìdas
IT1313702B1 (it) Processo per la preparazione di derivati 3-sostituiti di 4-fenil-piperidine.
EP0574271A3 (da)
HUP0104045A2 (hu) Eljárás 4-[(2',5'-diamino-6'-halogén-pirimidin-4'-il)-amino]-ciklopent-2-enilmetanol-származékok előállítására

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 841326

Country of ref document: ES